*A phase 3b, randomized, controlled, evaluator-blinded, parallel-arm, multicenter trial of patients 12 to 35 years of age with acne vulgaris (N=160). Subjects were randomized in a 1:1 ratio to receive a once-daily evening application of either Differin® Gel, 0.3% or tazarotene gel, 0.1% for 12 weeks.